Author:
Lian Jinrong,Lin Zhimin,Li Xiang,Chen Gang,Wu Depei
Reference42 articles.
1. Althaus AL, Ackley MA, Belfort GM, et al. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator. Neuropharmacology 2020; 181: 108333. 2020/09/26. DOI:https://doi.org/10.1016/j.neuropharm.2020.108333.
2. Boschloo L, Schoevers RA, Beekman AT, et al. The four-year course of major depressive disorder: the role of staging and risk factor determination. Psychother. Psychosom. 2014; 83: 279–288. 2014/08/15. DOI:https://doi.org/10.1159/000362563.
3. Chigareva O, Smirnova D, Astafeva D, et al. Comparing the anti-depressive effect of electroconvulsive therapy (ECT) versus transcranial magnetic stimulation (TMS) in the treatment of patients with depression. Psychiatr. Danub 2023; 35: 48–55. 2023/10/06.
4. Cipriani A, Koesters M, Furukawa TA, et al. Duloxetine versus other anti-depressive agents for depression. Cochrane Database Syst. Rev. 2012; 10: Cd006533. 2012/10/19. DOI:https://doi.org/10.1002/14651858.CD006533.pub2.
5. Cuijpers P, Quero S, Dowrick C, et al. Psychological treatment of depression in primary care: recent developments. Curr. Psychiatry Rep. 2019; 21: 129. 2019/11/25. DOI:https://doi.org/10.1007/s11920-019-1117-x.